Which has stronger valuation & earnings, SIBN or STEX?

SiBone has higher revenue and earnings than Biosig Technologies. SiBone is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $206.22M 3.26 -$18.90M -$0.39 N/A Biosig Technologies $40K 4,327.29 -$462.77M -$9.71 N/A

Which has stronger valuation and earnings, SGP or STEX?

Spyglass Pharma has higher earnings, but lower revenue than Biosig Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spyglass Pharma N/A N/A N/A N/A N/A Biosig Technologies $40K 4,327.29 -$462.77M -$9.71 N/A

Is SGP or STEX more profitable?

Spyglass Pharma's return on equity of 0.00% beat Biosig Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Spyglass Pharma N/A N/A N/A Biosig Technologies N/A -717.92% -336.75%

Biosig Technologies (STEX) Competitors

$0.95 +0.03 (+3.33%)

Closing price 04:00 PM Eastern

Extended Trading

$0.95 0.00 (-0.12%)

As of 07:56 PM Eastern

Compare

STEX vs. SSII, BVS, CBLL, SIBN, and SGP

Should you buy Biosig Technologies stock or one of its competitors? MarketBeat compares Biosig Technologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Biosig Technologies include SS Innovations International (SSII), Bioventus (BVS), CeriBell (CBLL), SiBone (SIBN), and Spyglass Pharma (SGP). These companies are all part of the "medical equipment" industry.

How does Biosig Technologies compare to SS Innovations International?

Biosig Technologies (NASDAQ:STEX) and SS Innovations International (NASDAQ:SSII) are both small-cap medical equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Biosig Technologies currently has a consensus target price of $8.00, indicating a potential upside of 740.25%. SS Innovations International has a consensus target price of $7.00, indicating a potential upside of 98.30%. Given Biosig Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe Biosig Technologies is more favorable than SS Innovations International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Biosig Technologies has a beta of 1.85, indicating that its stock price is 85% more volatile than the broader market. Comparatively, SS Innovations International has a beta of -1.88, indicating that its stock price is 288% less volatile than the broader market.

In the previous week, SS Innovations International had 1 more articles in the media than Biosig Technologies. MarketBeat recorded 2 mentions for SS Innovations International and 1 mentions for Biosig Technologies. Biosig Technologies' average media sentiment score of 1.89 beat SS Innovations International's score of 0.72 indicating that Biosig Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Biosig Technologies	Very Positive
SS Innovations International	Positive

Biosig Technologies has a net margin of 0.00% compared to SS Innovations International's net margin of -20.69%. SS Innovations International's return on equity of -23.00% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
SS Innovations International	-20.69%	-23.00%	-13.18%

7.2% of Biosig Technologies shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

SS Innovations International has higher revenue and earnings than Biosig Technologies. SS Innovations International is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	4,327.29	-$462.77M	-$9.71	N/A
SS Innovations International	$48.47M	14.58	-$12.13M	-$0.05	N/A

Summary

Biosig Technologies beats SS Innovations International on 10 of the 16 factors compared between the two stocks.

How does Biosig Technologies compare to Bioventus?

Biosig Technologies (NASDAQ:STEX) and Bioventus (NASDAQ:BVS) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

In the previous week, Bioventus had 3 more articles in the media than Biosig Technologies. MarketBeat recorded 4 mentions for Bioventus and 1 mentions for Biosig Technologies. Biosig Technologies' average media sentiment score of 1.89 beat Bioventus' score of 1.00 indicating that Biosig Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Biosig Technologies	Very Positive
Bioventus	Positive

Bioventus has a net margin of 4.94% compared to Biosig Technologies' net margin of 0.00%. Bioventus' return on equity of 29.97% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
Bioventus	4.94%	29.97%	9.52%

Bioventus has higher revenue and earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	4,327.29	-$462.77M	-$9.71	N/A
Bioventus	$576.30M	1.26	$22.73M	$0.41	21.17

Biosig Technologies has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market. Comparatively, Bioventus has a beta of 0.67, suggesting that its share price is 33% less volatile than the broader market.

Biosig Technologies currently has a consensus target price of $8.00, suggesting a potential upside of 740.25%. Bioventus has a consensus target price of $14.00, suggesting a potential upside of 61.29%. Given Biosig Technologies' higher probable upside, equities research analysts plainly believe Biosig Technologies is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

7.2% of Biosig Technologies shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 52.7% of Biosig Technologies shares are held by company insiders. Comparatively, 33.0% of Bioventus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Bioventus beats Biosig Technologies on 12 of the 17 factors compared between the two stocks.

How does Biosig Technologies compare to CeriBell?

Biosig Technologies (NASDAQ:STEX) and CeriBell (NASDAQ:CBLL) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Biosig Technologies presently has a consensus price target of $8.00, suggesting a potential upside of 740.25%. CeriBell has a consensus price target of $22.20, suggesting a potential upside of 22.31%. Given Biosig Technologies' higher probable upside, research analysts plainly believe Biosig Technologies is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, CeriBell had 5 more articles in the media than Biosig Technologies. MarketBeat recorded 6 mentions for CeriBell and 1 mentions for Biosig Technologies. Biosig Technologies' average media sentiment score of 1.89 beat CeriBell's score of 0.37 indicating that Biosig Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Biosig Technologies	Very Positive
CeriBell	Neutral

CeriBell has higher revenue and earnings than Biosig Technologies. CeriBell is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40K	4,327.29	-$462.77M	-$9.71	N/A
CeriBell	$95.07M	7.24	-$53.41M	-$1.63	N/A

Biosig Technologies has a net margin of 0.00% compared to CeriBell's net margin of -63.51%. CeriBell's return on equity of -38.19% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	-717.92%	-336.75%
CeriBell	-63.51%	-38.19%	-30.92%

7.2% of Biosig Technologies shares are held by institutional investors. 52.7% of Biosig Technologies shares are held by insiders. Comparatively, 20.1% of CeriBell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Biosig Technologies has a beta of 1.85, meaning that its stock price is 85% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

Summary

CeriBell beats Biosig Technologies on 9 of the 17 factors compared between the two stocks.

How does Biosig Technologies compare to SiBone?

SiBone (NASDAQ:SIBN) and Biosig Technologies (NASDAQ:STEX) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

98.1% of SiBone shares are held by institutional investors. Comparatively, 7.2% of Biosig Technologies shares are held by institutional investors. 4.0% of SiBone shares are held by insiders. Comparatively, 52.7% of Biosig Technologies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

SiBone currently has a consensus target price of $23.00, suggesting a potential upside of 51.92%. Biosig Technologies has a consensus target price of $8.00, suggesting a potential upside of 740.25%. Given Biosig Technologies' higher possible upside, analysts plainly believe Biosig Technologies is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

SiBone has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market. Comparatively, Biosig Technologies has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market.

In the previous week, SiBone had 3 more articles in the media than Biosig Technologies. MarketBeat recorded 4 mentions for SiBone and 1 mentions for Biosig Technologies. Biosig Technologies' average media sentiment score of 1.89 beat SiBone's score of 0.74 indicating that Biosig Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
SiBone	Positive
Biosig Technologies	Very Positive

SiBone has higher revenue and earnings than Biosig Technologies. SiBone is trading at a lower price-to-earnings ratio than Biosig Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$206.22M	3.26	-$18.90M	-$0.39	N/A
Biosig Technologies	$40K	4,327.29	-$462.77M	-$9.71	N/A

Biosig Technologies has a net margin of 0.00% compared to SiBone's net margin of -8.10%. SiBone's return on equity of -9.56% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Biosig Technologies	N/A	-717.92%	-336.75%

Summary

SiBone beats Biosig Technologies on 9 of the 16 factors compared between the two stocks.

How does Biosig Technologies compare to Spyglass Pharma?

Spyglass Pharma (NASDAQ:SGP) and Biosig Technologies (NASDAQ:STEX) are both small-cap manufacturing companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk, media sentiment and earnings.

Spyglass Pharma currently has a consensus price target of $45.00, suggesting a potential upside of 148.76%. Biosig Technologies has a consensus price target of $8.00, suggesting a potential upside of 740.25%. Given Biosig Technologies' higher possible upside, analysts clearly believe Biosig Technologies is more favorable than Spyglass Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Biosig Technologies	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Spyglass Pharma has higher earnings, but lower revenue than Biosig Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A
Biosig Technologies	$40K	4,327.29	-$462.77M	-$9.71	N/A

In the previous week, Spyglass Pharma and Spyglass Pharma both had 1 articles in the media. Biosig Technologies' average media sentiment score of 1.89 beat Spyglass Pharma's score of 1.87 indicating that Biosig Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Spyglass Pharma	Very Positive
Biosig Technologies	Very Positive

7.2% of Biosig Technologies shares are held by institutional investors. 52.7% of Biosig Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Spyglass Pharma's return on equity of 0.00% beat Biosig Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyglass Pharma	N/A	N/A	N/A
Biosig Technologies	N/A	-717.92%	-336.75%

Summary

Biosig Technologies beats Spyglass Pharma on 5 of the 9 factors compared between the two stocks.

Get Biosig Technologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STEX vs. The Competition

Export

Metric	Biosig Technologies	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$173.09M	$2.82B	$4.31B	$11.99B
Dividend Yield	N/A	N/A	9.93%	5.62%
P/E Ratio	-0.10	13.72	22.13	24.12
Price / Sales	4,327.29	407.41	210.60	84.96
Price / Cash	N/A	8.08	41.20	54.72
Price / Book	1.15	5.68	28.34	6.82
Net Income	-$462.77M	$7.39M	$118.48M	$337.52M
7 Day Performance	-19.31%	-2.30%	-2.41%	-0.96%
1 Month Performance	0.33%	-1.69%	0.23%	1.68%
1 Year Performance	N/A	3.40%	12.36%	26.88%

Biosig Technologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STEX Biosig Technologies	2.8902 of 5 stars	$0.95 +3.3%	$8.00 +740.2%	N/A	$173.09M	$40K	N/A	50	Positive News
SSII SS Innovations International	2.8134 of 5 stars	$3.53 -6.6%	$7.00 +98.3%	-16.2%	$756.50M	$42.49M	N/A	4
BVS Bioventus	4.5569 of 5 stars	$8.95 -1.0%	$14.00 +56.4%	N/A	$755.15M	$568.09M	21.83	1,200	Positive News
CBLL CeriBell	2.5069 of 5 stars	$18.14 -0.6%	$22.20 +22.4%	+3.7%	$692.45M	$89.06M	N/A	N/A	News Coverage Insider Trade
SIBN SiBone	2.2907 of 5 stars	$14.97 -1.0%	$23.00 +53.6%	-19.5%	$670.56M	$200.93M	N/A	350

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STEX) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biosig Technologies (STEX) Competitors

STEX vs. SSII, BVS, CBLL, SIBN, and SGP

How does Biosig Technologies compare to SS Innovations International?

Summary

How does Biosig Technologies compare to Bioventus?

Summary

How does Biosig Technologies compare to CeriBell?

Summary

How does Biosig Technologies compare to SiBone?

Summary

How does Biosig Technologies compare to Spyglass Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STEX vs. The Competition

Biosig Technologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biosig Technologies (STEX) Competitors

STEX vs. SSII, BVS, CBLL, SIBN, and SGP

How does Biosig Technologies compare to SS Innovations International?

Do analysts rate STEX or SSII?

Which has more risk and volatility, STEX or SSII?

Does the media favor STEX or SSII?

Is STEX or SSII more profitable?

Do insiders & institutionals hold more shares of STEX or SSII?

Which has stronger earnings and valuation, STEX or SSII?

Summary

How does Biosig Technologies compare to Bioventus?

Does the media favor STEX or BVS?

Is STEX or BVS more profitable?

Which has better earnings and valuation, STEX or BVS?

Which has more volatility and risk, STEX or BVS?

Do analysts prefer STEX or BVS?

Do insiders & institutionals hold more shares of STEX or BVS?

Summary

How does Biosig Technologies compare to CeriBell?

Do analysts recommend STEX or CBLL?

Does the media favor STEX or CBLL?

Which has stronger valuation and earnings, STEX or CBLL?

Is STEX or CBLL more profitable?

Do institutionals and insiders hold more shares of STEX or CBLL?

Which has more volatility & risk, STEX or CBLL?

Summary

How does Biosig Technologies compare to SiBone?

Do insiders & institutionals have more ownership in SIBN or STEX?

Do analysts recommend SIBN or STEX?

Which has more risk & volatility, SIBN or STEX?

Does the media prefer SIBN or STEX?

Which has stronger valuation & earnings, SIBN or STEX?

Is SIBN or STEX more profitable?

Summary

How does Biosig Technologies compare to Spyglass Pharma?

Do analysts rate SGP or STEX?

Which has stronger valuation and earnings, SGP or STEX?

Does the media favor SGP or STEX?

Do insiders and institutionals have more ownership in SGP or STEX?

Is SGP or STEX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STEX vs. The Competition

Biosig Technologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools